Fig. 2.

Location of WIPO Re:Search anthelmintic drug development partnerships within the product development pipeline. The majority of partnerships facilitated to date involve the sharing of compounds or compound libraries to be screened against the causative agents of schistosomiasis, soil-transmitted helminthiases, onchocerciasis, lymphatic filariasis, and neurocysticercosis. Partners mentioned in this figure include Aberystwyth University, Alnylam Pharmaceuticals, AstraZeneca (AZ), Drugs for Neglected Diseases initiative (DNDi), Eskitis Institute at Griffith University, GlaxoSmithKline (GSK), Liverpool School of Tropical Medicine (Liverpool STM), McGill University, MSD (known as Merck in the US and Canada), US National Institutes of Health (NIH), Swiss Tropical and Public Health Institute (Swiss TPH), University of British Columbia (UBC), University of California, San Francisco (UCSF), and University of Buea. Capacity-building partnerships are not included in the figure. Asterisks (∗, ∗∗, ∗∗∗) represent partnerships focused on multiple diseases.